Australia markets closed

Eagle Pharmaceuticals, Inc. (EGRX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.7300-0.1000 (-2.61%)
At close: 04:00PM EDT
3.7300 0.00 (0.00%)
After hours: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 48.33M
Enterprise value 104.60M
Trailing P/E 4.39
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.19
Price/book (mrq)0.19
Enterprise value/revenue 0.41
Enterprise value/EBITDA 1.87

Trading information

Stock price history

Beta (5Y monthly) 0.53
52-week change 3-77.61%
S&P500 52-week change 323.29%
52-week high 317.3200
52-week low 33.2100
50-day moving average 34.9416
200-day moving average 35.0308

Share statistics

Avg vol (3-month) 3146.22k
Avg vol (10-day) 388.12k
Shares outstanding 512.96M
Implied shares outstanding 613.37M
Float 88.37M
% held by insiders 112.02%
% held by institutions 176.67%
Shares short (15 Aug 2024) 4484.16k
Short ratio (15 Aug 2024) 44.43
Short % of float (15 Aug 2024) 45.79%
Short % of shares outstanding (15 Aug 2024) 43.74%
Shares short (prior month 15 July 2024) 4770.58k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 June 2023

Profitability

Profit margin 4.64%
Operating margin (ttm)15.94%

Management effectiveness

Return on assets (ttm)6.63%
Return on equity (ttm)4.88%

Income statement

Revenue (ttm)257.55M
Revenue per share (ttm)19.68
Quarterly revenue growth (yoy)-12.80%
Gross profit (ttm)N/A
EBITDA 62.33M
Net income avi to common (ttm)11.95M
Diluted EPS (ttm)0.8500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)15.35M
Total cash per share (mrq)1.18
Total debt (mrq)72.45M
Total debt/equity (mrq)28.75%
Current ratio (mrq)2.16
Book value per share (mrq)19.25

Cash flow statement

Operating cash flow (ttm)-9.32M
Levered free cash flow (ttm)38.31M